S.W. Kim

Discipline

Psychologie (2)

Type de document

Articles (6) Recensions (1)

Co-auteur

Date

Source

Mot-clé

Use (6) Human beings (5) thérapie (4) Treatment (4) Chemotherapy (4) Therapeutics (4) Lungs (4) Chemotherapy (4) Cancer (4) danger (3) survie (3) Survival (3) Poseidon (Greek deity) (3) Patients (3) Lungs--Cancer (3) Immunotherapy (3) Patients (3) Immunotherapy (3) recherche (2) adulte (2) Development (2) Rates (2) Weights and measures (2) Symptoms (2) Research (2) Adjustable rate mortgages (2) Months (2) Immunoglobulins (2) Expression (2) Research (2)

Documents écrit par S.W. Kim (6) | parle de S.W. Kim (0)

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
E.B. Garon et al.
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.
CMJ Wannan et al. (30 avr. 2024)
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
E.B. Garon et al.
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
M. Reck et al.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
M.L. Johnson et al. (20 févr. 2023)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
D.J. Klionsky et al.